InfuSystem Holdings, Inc. (INFU)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 4
Do Nothing: qualitativeScore is 2 (below the required floor of 3) — the upstream qualitative screen flagged a concern that disqualifies a fresh long — and the 20-day average dollar volume of ~$1.28M is below the $5M liquidity floor. The chart (uptrend consolidation above all key moving averages, ADX 34.8, RSI 60) is constructive, but both gates block before entry placement, so neither a pullback limit nor a breakout stop was constructed.
Company overview
InfuSystem Holdings, Inc. provides infusion pumps and related services across the U.S. and Canada, focusing on oncology and pain management. It operates through Integrated Therapy Services and Durable Medical Equipment Services, offering devices, consumables, and maintenance services to healthcare facilities.
Fundamental
fairInfuSystem is financially stable with improving profitability, but valuation concerns limit its margin of safety.
Financially healthy small-cap healthcare services business with improving profitability and strong cash conversion, low leverage, and no SEC going‑concern/covenant red flags. However, recent top‑line growth has flattened and a discounted‑cash‑flow model implies limited margin of safety at today’s price, so it reads more like a quality watchlist name than a clear bargain.
Sentiment
weakSentiment is neutral with no significant catalysts or retail interest in the near term.
No actionable directional catalyst sits in the 14-day window — the only forward event is a scheduled, neutral investor webcast (2026-09-24, announced confidence) — and the determinate sentiment delta cools from a mildly positive baseline (+0.17 on Q2-beat coverage) to flat (0.00), with retail coverage indeterminate; Red-Flag Screen clean, and with no market-rewarded bullish element in-window the setup reads quiet/absent rather than mixed.
Technical
goodThe stock is in a strong uptrend with positive momentum, but liquidity constraints limit tradability.
INFU is in a strong uptrend consolidation: price 12.32 sits above the SMA20 (12.16), SMA50 (11.19) and SMA200 (9.65), with EMA9/21 (12.29/12.10) stacked bullishly beneath. ADX14 at 34.80 confirms trend strength, and RSI14 at 60.16 shows healthy positive momentum without being overbought. MACD (0.26/0.31/-0.04) is positive but slightly below signal — momentum cooling within the six-week 11.8-12.7 range after the August re-rating. The one clearly weak frame is volume: 20-day average dollar volume is ~$1.28M, well under the $5M floor. The trade plan is suppressed: qualitativeScore 2 hard-blocks a fresh long, and the liquidity floor independently fails, so no entry type was constructed.
You’re looking at 2026-09-18 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.